Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
Carcinoma, Non-Small-Cell Lung|Bronchial Neoplasms|Carcinoma, Bronchogenic|Lung Diseases|Lung Neoplasms
dynamic changes of circulating tumor DNA in late stage NSCLC patients under Gefitinib treatment, 2 years
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.